Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch & LombBLCO -0.47%77 EV-to-EBIT is 33.48 as of Aug. 03, 2026, which is 55% below its 10-year median of 74.11. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.02 (Fairly Valued). The stock has 9 warning signs investors should review. Among 470 Medical Devices & Instruments companies, Bausch & Lomb ranks worse than 76.38% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bausch & Lomb's Enterprise Value for the quarter that ended in Jun. 2026 was $10,729 Mil.
Bausch & Lomb's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $324 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb EV-to-EBIT Related Terms
Bausch & Lomb EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bausch & Lomb's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's EV-to-EBIT falls into.
Bausch & Lomb's current Enterprise Value is $10,847 Mil.
Bausch & Lomb's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $324 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (BLCO) has a EV-to-EBIT of 33.48 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bausch & Lomb and its competitors. This is 55% below median its historical median of 74.11. Over the past decade, Bausch & Lomb's EV-to-EBIT has ranged from 24.18 to 425.35. According to the industry distribution chart, Bausch & Lomb ranks #359 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 76.4%.
Is Bausch & Lomb's EV-to-EBIT too high?
Bausch & Lomb's current EV-to-EBIT of 33.48 is 55% below median its 10-year median of 74.11. Over the past 10 years, this metric has ranged from a low of 24.18 to a high of 425.35. The Medical Devices & Instruments industry median EV-to-EBIT is 18.92. Bausch & Lomb's value of 33.48 is 77% above this industry median. Based on the distribution chart, Bausch & Lomb ranks #359 out of 470 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #359 out of 470 companies for EV-to-EBIT. This places Bausch & Lomb in the lower half of its industry. The industry median EV-to-EBIT is 18.92. Bausch & Lomb's value of 33.48 is 77% above this benchmark. Historically, Bausch & Lomb's own EV-to-EBIT has ranged from 24.18 to 425.35 over the past decade. While the company's 10-year median is 74.11 vs. the industry median of 18.92, Bausch & Lomb has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.92, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch & Lomb's current EV-to-EBIT of 33.48 is 77% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bausch & Lomb and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch & Lomb's current EV-to-EBIT is 33.48, which is 55% below median its own 10-year median of 74.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Fairly Valued. The stock's GF Value™ is $18.02, compared to a current price of $16.91 — trading 6.2% below its estimated fair value. The current EV-to-EBIT is 33.48, which is 55% below median its 10-year median of 74.11 and 77% above the Medical Devices & Instruments industry median of 18.92. Bausch & Lomb's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current EV-to-EBIT is 33.48 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of $16.91 is trading 6.2% below its estimated GF Value™ of $18.02.
GuruFocus considers Bausch & Lomb to be Fairly Valued.
Key valuation signals for BLCO:
EV-to-EBIT: 33.48 (55% below median its 10-year median of 74.11)
GF Value™: $18.02 vs. price of $16.91 (6.2% below fair value)
Industry Position: 77% above the Medical Devices & Instruments median (#359 of 470)
No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score
Get the complete analysis for BLCO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLCO has been successfully added to your 
